Drug Profile


Alternative Names: ALN-AAT

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Alpha 1 antitrypsin inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Alpha 1-antitrypsin deficiency

Most Recent Events

  • 28 Sep 2016 Pharmacodynamics and safety data from a phase I/II trial in Alpha 1-antitrypsin deficiency released by Alnylam Pharmaceuticals
  • 04 Aug 2015 ALN AAT is covered by patents in USA, Europe, Japan, Australia, New Zealand, South Korea and China
  • 01 Jul 2015 Phase-I/II clinical trials in Alpha 1-antitrypsin deficiency in United Kingdom (SC) (NCT02503683)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top